These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22911710)

  • 21. Who benefits most from adjuvant interferon treatment for melanoma?
    Gogas H; Abali H; Ascierto PA; Demidov L; Pehamberger H; Robert C; Schachter J; Eggermont AM; Hauschild A; Espinosa E
    Am J Ther; 2015; 22(1):54-60. PubMed ID: 24176884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon--comparison with tyrosinase rt-PCR.
    Domingo-Domènech J; Molina R; Castel T; Montagut C; Puig S; Conill C; Martí R; Vera M; Auge JM; Malvehy J; Grau JJ; Gascon P; Mellado B
    Oncology; 2005; 68(4-6):341-9. PubMed ID: 16020961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
    Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
    J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients.
    Lee JE; Abdalla J; Porter GA; Bradford L; Grimm EA; Reveille JD; Mansfield PF; Gershenwald JE; Ross MI
    Ann Surg Oncol; 2002 Jul; 9(6):587-93. PubMed ID: 12095976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J
    Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Current aspects of adjuvant therapy of malignant melanoma].
    Kähler KC; Egberts F; Hauschild A
    Hautarzt; 2010 Jun; 61(6):523-31; quiz 532-3. PubMed ID: 20512304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690.
    Rao UN; Ibrahim J; Flaherty LE; Richards J; Kirkwood JM
    J Clin Oncol; 2002 Apr; 20(8):2053-7. PubMed ID: 11956265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon.
    Pancoska P; Kirkwood JM; Bouros S; Spyropoulou-Vlachou M; Pectasides E; Tsoutsos D; Polyzos A; Markopoulos C; Panagiotou P; Castana O; Bafaloukos D; Fountzilas G; Gogas H
    PLoS One; 2014; 9(1):e86375. PubMed ID: 24475110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.
    Ives NJ; Suciu S; Eggermont AMM; Kirkwood J; Lorigan P; Markovic SN; Garbe C; Wheatley K;
    Eur J Cancer; 2017 Sep; 82():171-183. PubMed ID: 28692949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of the HLA-B27 antigen and the CTLA4 gene CT60/rs3087243 polymorphism with ankylosing spondylitis in Algerian population: A case-control study.
    Dahmani CA; Benzaoui A; Amroun H; Mecabih F; Sediki FZ; Zemani-Fodil F; Fodil M; Boughrara W; Mecheti B; Attal N; Mehtar N; Petit-Teixeira E; Boudjema A
    Int J Immunogenet; 2018 Jun; 45(3):109-117. PubMed ID: 29675891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
    Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
    Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant ipilimumab in stage III melanoma: New landscape, new questions.
    Eggermont AM
    Eur J Cancer; 2016 Dec; 69():39-42. PubMed ID: 27816830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
    Sosman JA; Unger JM; Liu PY; Flaherty LE; Park MS; Kempf RA; Thompson JA; Terasaki PI; Sondak VK;
    J Clin Oncol; 2002 Apr; 20(8):2067-75. PubMed ID: 11956267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer Stage I or II.
    Lee JE; Lu M; Mansfield PF; Platsoucas CD; Reveille JD; Ross MI
    Cancer; 1996 Aug; 78(4):758-63. PubMed ID: 8756369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
    Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
    Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up.
    Rusciani L; Petraglia S; Alotto M; Calvieri S; Vezzoni G
    Cancer; 1997 Jun; 79(12):2354-60. PubMed ID: 9191523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
    Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
    Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy.
    Grignol VP; Smith AD; Shlapak D; Zhang X; Del Campo SM; Carson WE
    Surg Oncol; 2015 Dec; 24(4):353-8. PubMed ID: 26690825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
    Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
    Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.